References of "Amory, Hélène"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailPharmacological effects of tiludronate in horses after long-term immobilization
Delguste, Catherine ULg; Amory, Hélène ULg; Doucet, Michèle et al

in BONE (2007), 41(3), 414-421

Introduction: Tiludronate, a bisphosphonate, has recently been introduced in veterinary medicine to treat orthopedic conditions in the horse. This study was designed to evaluate its effects on biochemical ... [more ▼]

Introduction: Tiludronate, a bisphosphonate, has recently been introduced in veterinary medicine to treat orthopedic conditions in the horse. This study was designed to evaluate its effects on biochemical biomarkers of bone metabolism and on bone density and structure in an experimental model of disuse osteoporosis induced by cast application in horses. Methods: Two groups of eight horses were immobilized during 8 weeks. The first group (P-group) received a placebo, and the second group (T-group) received tiludronate 1 mg/kg by slow IV infusion. Both treatments were administered twice, 28 days apart. Immobilization consisted of stall rest with the left forelimb packed in a fiberglass cast. It was followed by a 4-week remobilization period and an 8-week standardized training protocol. One biomarker of bone resorption, the C-telopeptides of type 1 collagen cross-links (CTX-1) and one biomarker of bone formation, the bone isoenzyme of alkaline phosphatase (bone ALP), were assessed. Metacarpus III (MCIII) bone mineral density (BMD) and speed of sound (SOS) were evaluated respectively by dual energy X-ray absorptiometry (DEXA) and quantitative ultrasonography (QUS). Lameness was regularly assessed during the remobilization and training periods. Group- and time-related effects were tested by analysis of variance on repeated measurements. Results: A rapid, transient and significant decrease in CTX-1 concentration was seen after each treatment in the T-group only. No significant differences between groups were seen in the evolution of bone ALP activity. At the end of the experiment, the loss of MCIII BMD measured by DEXA in the immobilized limb was significantly less in the T-group than in the P-group. The MCIII SOS measured by QUS did not significantly vary within or between groups throughout the study. Discussion and conclusions: Tiludronate was found to significantly reduce bone resorption during immobilization, as well as to prevent long-term osteopenia in the immobilized limb. Disuse osteopenia did not affect the lateral superficial cortex of MCIII. (C) 2007 Elsevier Inc. All rights reserved. [less ▲]

Detailed reference viewed: 20 (1 ULg)
Peer Reviewed
See detailTetanus in the horse
Van Galen, Gaby ULg; Amory, Hélène ULg

Conference (2007, April 28)

Detailed reference viewed: 23 (2 ULg)
Full Text
Peer Reviewed
See detailPrévenir la myopathie atypique du cheval au pré par la gestion raisonnée des pâtures et des chevaux établie sur base de l'identification des facteurs de risques de la maladie
Votion, Dominique ULg; Delguste, Catherine ULg; Amory, Hélène ULg et al

in 33ème Journée de la Recherche Equine (2007, March 08)

La myopathie atypique (MA) des équidés est un syndrome de destruction musculaire massive et sévère affectant des chevaux séjournant en pâture. Cette myopathie, généralement fatale endéans les 72 heures ... [more ▼]

La myopathie atypique (MA) des équidés est un syndrome de destruction musculaire massive et sévère affectant des chevaux séjournant en pâture. Cette myopathie, généralement fatale endéans les 72 heures, est rencontrée en France de manière significative et récurrente depuis l’automne 2002. La Belgique a reconnu ses premiers cas de MA au cours de l’automne 2000. Grâce à la collecte systématique des données épidémiologiques et cliniques des cas belges confirmés par analyse histologique de muscles prélevés post mortem, il a été possible de définir les facteurs de risques contribuant à l’émergence de la maladie dans une prairie et/ ou au sein d’un élevage. A partir de ces facteurs de risques identifiés, des mesures de prévention de la MA sont proposées et discutées. [less ▲]

Detailed reference viewed: 114 (7 ULg)
Peer Reviewed
See detailThe composition of the inflammatory infiltrate in 3 cases of polyneuritis equi
Van Galen, Gaby ULg; Sandersen, Charlotte ULg; Delguste, Catherine ULg et al

in In Proccedings of the Second congress of the European College od Equine Internal Medicine (ECEIM) (2007, February 02)

Detailed reference viewed: 23 (7 ULg)
Full Text
Peer Reviewed
See detailMorphological alterations in oxidative muscles and mitochondrial structure associated with equine atypical myopathy
Cassart, Dominique ULg; Baise, Etienne ULg; Cherel, Yann et al

in Equine Veterinary Journal (2007), 39(1), 26-32

REASONS FOR PERFORMING STUDY: There is a lack of well documented studies about muscular lesions in equine atypical myopathy (EAM). <br /> <br />OBJECTIVES: To characterise morphopathological changes of ... [more ▼]

REASONS FOR PERFORMING STUDY: There is a lack of well documented studies about muscular lesions in equine atypical myopathy (EAM). <br /> <br />OBJECTIVES: To characterise morphopathological changes of striated muscles and myocardium, to progress understanding of this disease. <br /> <br />METHODS: Thirty-two horses age 0.5-7 years kept on pasture were referred for a sudden ataxia/myoglobinuria syndrome. Clinical examination (stiffness, muscle pain, muscle fasciculations, abnormal gait, recumbency, myoglobinuria, tachycardia, sweating) and plasma CPK, LDH and AST levels were consistent with extensive myonecrosis and, together with anamnestic data, with so-called 'equine atypical myopathy' (EAM), a disease of unknown aetiology reported since 1939. Macroscopic and microscopic (histology, histoenzymology, ultrastructure) lesions were evaluated. <br /> <br />RESULTS: Necropsic examination revealed large areas of muscle necrosis, the extent and severity of which varied between cases and muscles, but which were clearly more constant and severe in respiratory and postural muscles and in the myocardium. Histology highlighted a multifocal and monophasic process compatible with Zenker degeneration/necrosis that mostly and segmentally affected type 1 fibres. Histochemical evaluation revealed a weak and disorganised pattern of NADH tetrazolium reductase staining, the absence of calcium salts precipitates and a dramatic accumulation of lipid droplets. Ultrastructural examination often revealed fibres of which the sole modifications were altered mitochondria and sarcoplasmic lipidosis. <br /> <br />CONCLUSIONS: Taken together, the data suggest that a primary alteration of mitochondria should be considered, although secondary mitochondrial abnormalities have yet to be ruled out. <br /> <br />POTENTIAL RELEVANCE: The morphological features gathered here reveal that EAM shares most of the characteristics of toxic myopathies. [less ▲]

Detailed reference viewed: 224 (19 ULg)
Peer Reviewed
See detailCleft Palate (CP): not only a diagnosis in foals
Van Galen, Gaby ULg; Delguste, Catherine ULg; Verwilghen, Denis ULg et al

Poster (2007, January)

Detailed reference viewed: 24 (8 ULg)
Full Text
See detailLe syndrome Piro-like chez le cheval
Sandersen, Charlotte ULg; Pittel, PH; Amory, Hélène ULg

in Proceedins of the 24th Annual Congress of the Belgian Equine Practitioners Society (BEPS) (2007)

Detailed reference viewed: 38 (1 ULg)
Full Text
See detailLe syndrome Piro-like: diagnostic différentiel sur base des symptômes et cas cliniques de cas de syndrome de piro-like incluant les moyens de diagnostic
Amory, Hélène ULg; Pittel, PH

in Proceedings of the Annual meeting of the French Equine Veterinary Association (AVEF) (2007)

Detailed reference viewed: 21 (2 ULg)
Full Text
See detailComment aborder un cas de fièvre d’origine inconnue
Amory, Hélène ULg

in Proceedings of the Annual meeting of the French Equine Veterinary Association (AVEF) (2007)

Detailed reference viewed: 9 (2 ULg)
Full Text
Peer Reviewed
See detailSymptomatic approach: icterus
Amory, Hélène ULg

in Proceedings of first Belgian International Congress of Equine Veterinarians and farriers (Hippos 2007) (2007)

Detailed reference viewed: 14 (0 ULg)
Full Text
Peer Reviewed
See detailDiagnostic differentiel du syndrome "piro-like" chez les équidés
Sandersen, Charlotte ULg; Amory, Hélène ULg

in Bulletin des Journées Nationales des GTV (2007)

Detailed reference viewed: 21 (2 ULg)
Full Text
Peer Reviewed
See detailApproche cliniques de la fièvre inconnue chez le cheval
Sandersen, Charlotte ULg; Amory, Hélène ULg

in Bulletin des journées nationales des GTV (2007)

Detailed reference viewed: 21 (1 ULg)
Full Text
Peer Reviewed
See detailPharmacologie clinique des bisphosphonates : revue de littérature axée sur le tiludronate chez le cheval.
Delguste, Catherine ULg; Lepage, Olivier M; Amory, Hélène ULg et al

in Annales de Médecine Vétérinaire (2007), 151

Detailed reference viewed: 29 (3 ULg)
Full Text
Peer Reviewed
See detailDiagnostic différentiel des souffles cardiaques en période néonatale chez le poulain
Amory, Hélène ULg

in Nouveau Praticien Vétérinaire Equine (2007)

Detailed reference viewed: 5 (1 ULg)
Peer Reviewed
See detailComparative pharmacokinetics of two intravenous dosage rates of tiludronate in healthy adult horses
Delguste, Catherine ULg; Amory, Hélène ULg; Guyonnet, Jérôme et al

Conference (2007)

Plasma and urine pharmacokinetics of tiludronate administered once daily as an intravenous bolus of 0.1 mg/kg for ten consecutive days (group 1, n=6) was compared to a single slow infusion of 1 mg/kg ... [more ▼]

Plasma and urine pharmacokinetics of tiludronate administered once daily as an intravenous bolus of 0.1 mg/kg for ten consecutive days (group 1, n=6) was compared to a single slow infusion of 1 mg/kg (group 2, n=6) in healthy adult horses. Plasma samples were collected at regular intervals for a period of 16 and 7 days in groups 1 and 2 respectively. Continuous urine collection for determination of cumulative urinary excretion of tiludronate was performed during 16 and 7 days in groups 1 and 2 respectively, and over 24-hour periods every 10 days until 60 days after the last tiludronate administration in both groups. Tiludronate concentrations were obtained in all plasma and urine samples using HPLC with UV detection. Plasma pharmacokinetic parameters were determined using a noncompartmental approach. Group 1 mean (± SD) AUCss was 3.76 (±0.698) mg.h.L-1 and group 2 mean (± SD) AUCtot was 39.07 (±3.699) mg.h.L-1. Mean (± SD) clearance (Cl) was 0.027 (±0.0042) and 0.026 (±0.0022) L.h-1.kg-1 in groups 1 and 2, respectively. Neither the dose corrected AUC (p=0.724) nor the Cl (p=0.528) were statistically different between groups. Relative plasma bioavailability (infusion versus bolus) was 103%. Cumulative urine tiludronic acid excretion could not be compared between groups due to analytical limitations (LOQ of 0.025 mg.L-1), which led to numerous missing data particularly in group 1, and an inability to conduct appropriate statistical and pharmacokinetic analyses. In conclusion, both dosage rates of tiludronate were considered bioequivalent with regards to plasma pharmacokinetics. [less ▲]

Detailed reference viewed: 28 (1 ULg)
Full Text
Peer Reviewed
See detailChange in blood antioxidant status of horses moved from a stable following diagnosis of equine motor neuron disease
Delguste, Catherine ULg; de Moffarts, B.; Kirschvink, N. et al

in Canadian Veterinary Journal = Revue Vétérinaire Canadienne (2007), 48(11), 1165-1167

The antioxidant status of 10 horses living in stable 1 where 2 cases of equine motor neuron disease had previously been diagnosed was assessed before and 9 weeks after moving to another stable. Duration ... [more ▼]

The antioxidant status of 10 horses living in stable 1 where 2 cases of equine motor neuron disease had previously been diagnosed was assessed before and 9 weeks after moving to another stable. Duration of residence in stable 1, subsequent moving, or both, significantly affected several parameters of the antioxidant status. [less ▲]

Detailed reference viewed: 224 (6 ULg)
Full Text
Peer Reviewed
See detailHistory and clinical features of atypical myopathy in horses in Belgium (2000-2005)
Votion, D. M.; Linden, Annick ULg; Saegerman, Claude ULg et al

in Journal of Veterinary Internal Medicine (2007), 21(6, Nov-Dec), 1380-1391

Background: The emergent nature of atypical myopathy or atypical myoglobinuria (AM) necessitates precise description of its clinical and epidemiologic features. Purpose: To define key features of AM to ... [more ▼]

Background: The emergent nature of atypical myopathy or atypical myoglobinuria (AM) necessitates precise description of its clinical and epidemiologic features. Purpose: To define key features of AM to help practitioners recognize the disease and to advise owners to take preventive measures. Animals: Belgian cases of AM confirmed by histology (CC horses; n = 57) from autumn 2000 to spring 2005 were included in the study. Co-grazing horses (Co-G horses; n = 77) that remained free of any abnormal clinical signs constituted a control croup. Methods: History, environmental characteristics, clinical signs, and laboratory results associated with AM were determined by a retrospective case series study. Results: Young horses in poor or normal body condition were found to be at risk for AM. Pastures were characterized by poor natural drainage and vegetation of low nutritional value. Features of AM were seasonal occurrence, apparent link with weather conditions fie, lack of solar radiation with no heavy frost and an excess of precipitation or relative humidity), sudden onset of clinical signs, and rapid death. Evaluation of serum creatine kinase activity indicated severe muscle destruction in CC horses and subclinical disease in a few Co-G horses. Conclusions: The association of AM with specific environmental conditions and individual animals suggests that young horses should not be pastured on bare premises subject to humidity when the weather has been very wet and cold for several days. Management of AM outbreaks should include control of Co-G horses who are apparently healthy. [less ▲]

Detailed reference viewed: 287 (29 ULg)